| Date | Title | Description | |
|---|---|---|---|
| 02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
| 24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
| 09 Jul 2020 | On business and financial situation | ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 11 Aug 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 3 August and 10 August 2023 | Download |
| 03 Aug 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 26 July 2023 and 2 August 2023 | Download |
| 28 Jul 2023 | On business and financial situation | ROVI informs on the evaluation process to obtain marketing authorisation for Risvan® | Download |
| 05 Jul 2023 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the second quarter of 2023 | Download |
| 26 Jun 2023 | Other relevant information | The Company informs about the dividends payment | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 21 Feb 2013 | Información sobre resultados (2) | Download | |
| 21 Feb 2013 | Información sobre resultados | Download | |
| 21 Feb 2013 | Informe Anual de Gobierno Corporativo 2012 | Download | |
| 08 Nov 2012 | Información financiera intermedia | Download | |
| 08 Nov 2012 | Información sobre resultados | Download |